Ligand id: 6508

Name: emricasan

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 9
Hydrogen bond donors 4
Rotatable bonds 15
Topological polar surface area 150.9
Molecular weight 569.18
XLogP 3.87
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Clinical candidate being investigated as a treatment for liver failure, including that ensuing from hepatitis C infection and nonalcoholic steatohepatitis. Click here to view emricasan related clinical trials registered with ClinicalTrials.gov. This drug candidate has been granted orphan designation by the US FDA, for the treatment of liver transplant patients with reestablished fibrosis. Drug treatment is intended to delay the progression to cirrhosis and end-stage liver disease in these patients.
Mechanism Of Action and Pharmacodynamic Effects
Emricasan irreversibly inhibits caspase proteases and is designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. It is postulated that this action has the potential to interrupt the progression of liver disease [1].